1Weissman SM,BurtR,Church J,Erdman S,Hampel H, Holter S, Jasperson K, Kalady MF, Haidle JL, Lynch HT, Palaniappan S, Wise PE, Senter L. Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J Genet Couns 2012; 21:484-493 [PMID: 22167527 DOI: 10.1007/s10897-011-9465-7].
2Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009; 11:42-65 [PMID: 19125127 DOI: 10.1097/GIM.0b013e31818fa2db].
3Egoavil C, Alenda C, Castillejo A, Paya A, Peiro G, S~nchez-Heras AB, Castillejo MI, Rojas E, Barbera VM, Ciguenza S, Lopez JA, Pi~ero O, Roman MJ, Martinez-Escoriza JC, Guarinos C, Perez-Carbonell L, Aranda FI, Soto JL. Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS One 2013; 8:e79737 [PMID: 24244552 DOI: 10.1371/journal. pone.0079737].
4Liu T, Wahlberg S, Burek E, Lindblom P, Rubio C, Lindblom A. Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer. Genes Chromosomes Cancer 2000; 27:17-25 [PMID: 10564582].
5Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000; 37:641-645 [PMID: 10978352].
6Rubenstein JH, Enns R, Heidelbaugh J, Barkun A. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome. Gastroenterology 2015; 149: 777-782; quiz e16-e17 [PMID: 26226577 DOI: 10.1053/j.gastro.2015.07.036].
7Hampel H. NCCN increases the emphasis on genetic/familial high-risk assessment in colorectal cancer. J Natl Compr Canc Netw 2014; 12:829-831 [PMID: 24853227].
8Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Moller P, Myrhoj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJ, Rahner N, Wijnen JT, J~irvinen HJ, MOslein G. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013; 62:812-823 [PMID: 23408351 DOI: 10.1136/ gutjnl-2012-304356].
9Barrow E, Hill J, Evans DG. Cancer risk in Lynch Syndrome. Fam Cancer 2013; 12:229-240 [PMID: 23604856 DOI: 10.1007/s10689-013-9615-1].
10Perez-Cabornero L, Infante M, Velasco E, Lastra E, Miner C, Duran M. Genotype-phenotype correlation in MMR mutation-positive families with Lynch syndrome. Int J Colorectal Dis 2013; 28:1195-1201 [PMID: 23588873 DOh 10.1007/s00384- 013-1685-x].
